Kamal Adawi, Chief Financial Officer of Fate Therapeutics Inc., filed a Form 4 on November 4, 2026, disclosing a sale of 6,582 shares of common stock on November 3, 2026, to cover tax withholding obligations connected to a vesting RSU award.
Key Highlights
- Reporting person and role: Kamal Adawi, Chief Financial Officer of Fate Therapeutics Inc. (NASDAQ:FATE)
- Transaction date: November 3, 2026
- Shares disposed: 6,582 shares of common stock, coded as a sale (S), disposed of (D)
- Weighted average price: $2.0548 per share, with individual sale prices ranging from $2.020 to $2.084 per share, according to the filing
- Purpose: Shares were sold to cover tax withholding obligations in connection with the vesting of 18,750 shares of common stock underlying RSUs granted on October 20, 2025
- Remaining beneficial ownership: 93,418 shares of common stock held directly following the transaction
- Sell-to-cover basis: The filing states the sales were automatically executed pursuant to an irrevocable election and "were not made at the discretion of the Reporting Person"
Adawi RSU Vesting Triggers Automatic Sell-to-Cover Transaction at Fate Therapeutics
According to the Form 4 filed with the SEC, Kamal Adawi, the Chief Financial Officer of Fate Therapeutics Inc. (NASDAQ:FATE), disposed of 6,582 shares of common stock on November 3, 2026. The filing identifies the transaction code as "S" (sale) with the shares marked as disposed of (D). The weighted average sale price was reported as $2.0548 per share, with the actual sale prices spanning a range from $2.020 to $2.084 per share.
The filing explains that these shares were sold to satisfy tax withholding obligations arising from the vesting of 18,750 shares of common stock underlying restricted stock units (RSUs) previously granted to Adawi on October 20, 2025. The Form 4 notes that the sales were executed automatically under an irrevocable sell-to-cover election and were not discretionary on the part of the reporting person. The filing further states that full details on shares sold at each price within the stated range will be provided upon request by the Commission staff, the issuer, or a security holder.
Following the reported transaction, Adawi's direct beneficial ownership of Fate Therapeutics common stock stood at 93,418 shares, as reported in the filing. The Form 4 was signed on November 4, 2026 by Cindy Tahl, acting as Attorney-in-Fact for the reporting person.
What Was Disclosed
Fate Therapeutics CFO Kamal Adawi's Form 4 discloses the automatic sale of 6,582 common shares on November 3, 2026, at a weighted average price of $2.0548, solely to cover taxes on a vesting RSU award, leaving him with 93,418 shares held directly.



Please wait processing your request...